- In October 2024, At the AAO 2024 meeting, Alcon showcased its innovations, including the Voyager DSLT for glaucoma treatment, UNIFEYE and UNIPEXY handheld gas delivery systems, and pivotal data for AR-15512, a dry eye treatment. These advancements aimed to improve outcomes and surgical efficiency
- In September 2024, EssilorLuxottica and Meta have extended their partnership, entering a long-term agreement to develop multi-generational smart eyewear products. Building on the success of Ray-Ban Meta glasses, the companies aim to shape the future of wearable technology together
- In OCTOBER 2024, Bausch + Lomb presented new scientific data and educational events at the 2024 AAO meeting in Chicago. Highlights included studies on the enVista Envy IOL, TENEO Excimer Laser, VYZULTA, and presentations on Blink Nutritears, MIEBO, and Xiidra
- In April 2024, AbbVie has completed its acquisition of Cerevel Therapeutics, enhancing its neuroscience portfolio. The acquisition includes Cerevel’s promising clinical-stage assets like Emraclidine for schizophrenia and Tavapadon for Parkinson's disease, strengthening AbbVie’s position in neurology and psychiatry
- In September, 2023, Novartis completed the divestment of its 'front of eye' ophthalmology assets to Bausch + Lomb for up to USD 2.5 billion, including USD 1.75 billion in upfront cash and potential milestone payments. The deal included Xiidra®, SAF312, AcuStream, and OJL332. Novartis advanced its strategy to focus on prioritized therapeutic areas for future growth
